Introduction
Acute Myeloid Leukemia (AML) represents a molecularly diverse group of malignant hematopoietic cancers resulting in the accumulation of marrow blasts with arrested differentiation. Treatment strategies for AML include intensive chemotherapy, which in most cases is the only option for longterm survival, however, approximately 15% of elderly patients die due to treatment complications and only 50% achieve remission (1). Despite considerable research, AML therapy has remained static for almost four decades, with poor outcomes in the elderly (2) . The importance of T cells for anti-leukemic function has been demonstrated in models of graft-versus-leukemia after allogeneic stem cell transplantation, whereby depletion of T cells abrogates this beneficial effect (3) . T cells produce cytokines like IFNγ and IL-2, which play a crucial role in anti-leukemic immunity (4, 5) .
However, T cells within AML patients are found to be functionally defective as they are impaired numerically, phenotypically and genetically (6) . It has previously been demonstrated that these defective T cells may partly be due to the suppressive function of regulatory T cells (Tregs) (7) .
Indeed, AML patients have abnormally high levels of Tregs within their peripheral blood (PB) and bone marrow (BM) compared to healthy donors (8) . The presence of high Treg levels in AML patients correlate with poor clinical outcomes (9) . This increase of Tregs has been attributed to AML blasts, which increase the frequency of Tregs through a variety of mechanisms including those linked to the effects of B7-H1 (10), indoleamine 2,3-dioxygenase (11) and CD200 (12) . Depletion of Tregs in vivo using an interleukin-2 diphtheria toxin in a murine AML model resulted in an enhancement of the frequency of cytotoxic T lymphocytes and a reduced tumor burden (13) . The importance of Tregs in dampening the anti-leukemic response is evident as their depletion results in an augmented immune response.
Tregs, however, are not a homogenous population as they contain cells with varying suppressive and migratory properties (14) . Tregs can express chemokine receptors that are tissue specific, enabling them to localize within the tissue (15) . The role of distinct Treg subsets in AML is currently not known, however, a functionally active Treg subset should have a high BM migratory capacity (16) Author Manuscript Published OnlineFirst on December 2, 2013; DOI: 10.1158/1078-0432.CCR- highly functional Tregs in healthy donors (17, 18) and in various diseases like malaria (19) , diabetes (20) and cancer (21) . TNFR2+ Tregs have higher expression of regulatory markers including CTLA4 and proliferation markers like Ki-67 compared to TNFR2-Tregs (17, 22) . These Tregs can be induced by either TCR ligation or by the presence of TNF (23) , a cytokine detected at high levels in the serum and BM of AML patients (24, 25) . Moreover, CXCL12, a chemokine secreted at high levels by marrow stromal cells and AML cells, has been demonstrated to promote TNFR2 expression on T cells (26, 27) . We therefore, hypothesized that TNFR2+ Tregs may be readily induced and would identify the most disease relevant Treg population in AML patients.
As epigenetic mechanisms play a key role in the development and progression of AML, epigenetic-targeting agents such as the hypomethylating agent, azacitidine, have recently entered the therapeutic armamentarium for AML (28, 29) . The epigenetic modifying effects of hypomethylating agents may be enhanced in combination with histone deacetylase inhibitors (HDACi) (30) . Although azacitidine has been demonstrated to enhance overall survival in some AML patients (31) , it can also increase FOXP3 expression and Treg levels, both in vivo (after stem cell transplantation) and in vitro (32, 33) . In contrast, a recent review suggested that the HDACi, panobinostat at low doses can decrease FOXP3 expression and reduce Treg levels (34 Pharmingen): anti-CD3, anti-CD4, anti-CD8, anti-TNFR2, anti-CD25, anti-CTLA4, anti-CD39, anti-CD73 and anti-CXCR4. For all samples, cells were also stained with a fixable dead cell stain (invitrogen). Live leukocytes were identified with anti-CD45 (eBioscience) prior to analysis of Tregs levels. Intracellular levels of FOXP3 and Ki67 were determined using firstly a fixation/permeabilization buffer kit (eBioscience) followed by staining with anti-FOXP3 (eBioscience) and anti-Ki67 (BD Pharmingen). Flow cytometry data was acquired on a Becton Dickinson LSR II using Diva software, collecting a minimum of 150,000 events per sample. Isotype matched antibodies were used as controls with all samples. Data were analyzed using Flowjo software (TreeStar).
Migration assays. CD4 T cells were isolated from healthy PBMCs using the INFLUX flow cytometry-based cell sorter. Migration assays were performed as previously described (21) . In brief, CXCL12 detection. ProcartaPlex Immunoassay Kit-Magnetic beads were to determine the level of CXCL12 present in the BM fluid and PB serum of AML patients. Quantification of CXCL12 was performed according to the manufacturer's instructions using a magnetic plate holder (Affymetrix). Samples were acquired on a luminex instrument, collecting a minimum of 100 events. Results were analyzed using the luminex instrument. 
Statistics. Statistical significance was determined by performing unpaired t-tests between healthy
and AML samples. Paired t-tests were performed when comparing AML samples before and after treatment with azacitidine and panobinostat. P<0.05 was considered to be significant. Statistical analyses were performed using GraphPad Prism. proportions were significantly enhanced at EOC3 when compared to screening, exceeding the normal range observed in healthy donors (Fig. 1B) . The absolute number of CD4 T cells was also significantly higher (p<0.05) at EOC3, when compared to screening (Fig. 1S) . To investigate the proportion of Tregs within CD4 T cells, CD25
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Elevated
hi T cells were gated on FOXP3 expression to identify
Tregs. CD127 expression within the CD25 hi T cells was also observed to be at low levels, confirming the identity of Tregs. The proportion of Tregs (CD25 hi FOXP3+) was compared between healthy donors and AML patients (Fig. 1C ). Consistent with a previous study (8), we observed Treg proportions to be significantly higher in patients (mean = 5.5%) compared to healthy donors (mean = 0.7%). Strikingly, Treg proportions were halved after one month of azacitidine and panobinostat treatment (mean = 2.4%) and this was sustained at three months of treatment (mean = 2.5%) (Fig.   1D ).
Tregs with high migratory capacity to the BM express TNFR2.
TNFR2 expression on Tregs identifies a population of potent suppressor T cells in healthy conditions (17) . Indeed, we also observed significant increases in the proliferation of effector T cells upon depletion of TNFR2+ Tregs when compared to the non-depleted control wells, but not upon depletion of TNFR2-Tregs ( Fig. 2S ), confirming TNFR2+ Tregs are potent suppressor cells. To characterize TNFR2+ Tregs in AML, we assessed the levels and phenotype of TNFR2+ and TNFR2-Tregs comparatively in healthy and AML donors. Tregs from patients had a higher expression level of TNFR2 when compared to healthy Tregs (p<0.01) ( Fig. 2A ). Additionally, patients had an almost 10-fold higher percentage of total TNFR2+ Tregs when compared to healthy donors ( Fig. 2A ). While TNFR2+ Tregs had higher levels of CTLA4 and CD73 compared to TNFR2-Tregs, there was no difference in CD39 expression level, which was high in both populations (Fig. 2B ). CTLA4 dampens effector T cell function while CD39 and CD73 can generate adenosine, which has immunosuppressive properties (14, 38) . The proportion of both CD39 and CD73 were also 9-fold higher on TNFR2+ Tregs than on TNFR2-Tregs in healthy donors (data not shown). TNFR2+ Tregs also contained a higher proportion of proliferating cells, as demonstrated by increased proportion of cells with high intracellular Ki67 expression than the TNFR2-subset (p<0.0001) (Fig. 2B ). This Treg subset produced significantly higher levels of the immunoregulatory cytokines, IL-10 and
TGFβ when compared to TNFR2-Tregs (Fig. 2C) . The above data supports a more potent regulatory phenotype for TNFR2+ than TNFR2-Tregs. In all of the above phenotypic analyses, we did not observe any significant differences between TNFR2+ Tregs isolated from healthy and AML donors.
To further test the potential relevance of TNFR2+ Tregs in patients, we determined the migratory potential of these Tregs to the BM by firstly assessing CXCR4 expression levels. As shown in figure 2D , TNFR2+ Tregs had significantly higher levels (6.8 fold higher) of CXCR4 compared to the TNFR2-fraction. Overall a positive correlation (p<0.0001) was observed between TNFR2 and CXCR4 expression levels on Tregs (Fig. 3S) . Additionally, we performed migration assays to determine if TNFR2+ Tregs were capable of migrating towards the BM fluid of AML patients. We observed that the BM fluid was able to attract an increased number of CD25 hi T cells when compared to media alone (p=0.06) (data not shown). Furthermore, within the CD25 hi T cell subset, a significantly higher number of TNFR2+ cells migrated towards the AML BM fluid when compared to the TNFR2-subset (p<0.0001) (Fig. 2D ).
Azacitidine and panobinstat therapy selectively lowers TNFR2+ but not TNFR2-Tregs in the PB of AML patients.
To determine if TNFR2+ Tregs were altered upon treatment, flow cytometry was performed at EOC1 and EOC3 of treatment. We observed a significant reduction of TNFR2 expression levels within Tregs as well as the percentage of total TNFR2+ Tregs at EOC1 when compared to screening, and these levels remained low at EOC3 (Fig. 3A and B 
within human tumors (39) . FOXP3 levels were significantly reduced on treatment within the TNFR2+CD25 hi T cell subset (Fig. 3C ) while no change was observed within the TNFR2-CD25 hi T cell subset (data not shown). Similarly, CTLA4 levels within the TNFR2+CD25 hi T cell subset were also reduced at EOC1 of treatment when compared to screening levels (Fig. 3C ). These results demonstrate that treatment reduces the proportion as well as potentially alters the function of TNFR2+ Tregs within AML patients. As several recent papers have demonstrated the existence of a FOXP3+CD25 low Treg subset, we also determined the levels of CD25 expression within TNFR2+FOXP3+ T cells (40) . Our results demonstrate TNFR2+FOXP3+ T cells have high expression levels of CD25 compared to the TNFR2-subset (Fig. 4S) . Additionally, we demonstrate that the levels of TNFR2+FOXP3+ T cells are higher in the PB of patients compared to healthy donors and that these levels are reduced on treatment (Fig. 4S ).
Response to epigenetic-targeted therapy is associated with a significant reduction in TNFR2+
Tregs within the BM.
As AML originates within the BM, it is important to determine if the results obtained in the PB were when compared to TNFR2-Tregs in the BM at screening (data not shown). These BM TNFR2+ Treg proportions (mean; SEM=4.5%; 1.3) were similar to that found in the PB (mean; SEM =5.06%; 1.1) of patients. There was also a trend for reduced TNFR2+ Treg proportions in the BM at EOC1 when compared to screening (p=0.07) (Fig. 4A) . When patients were categorized into clinical responders and non-responders at EOC1 based on hematologic reductions in blast cell counts (36, 37), a significant difference in TNFR2+ Treg proportions was observed. As shown in figure 4B , while both responders and non-responders had a reduction in TNFR2+ Tregs in the PB, only clinical responders to treatment had a significant reduction (p<0.05) in TNFR2+ Tregs in their BM when compared to non-responders. Additionally, we observed no significant changes in the absolute cell counts of TNFR2+ Tregs in the PB at EOC1 between clinical responders and non-responders (data not shown).
Although it would have been informative to perform absolute cell counts within the BM, this was not performed at the time of sample collection and this data is not available. Within the BM samples, the responder cohort consisted of 4 patients (2 MDS and 2 AML) at complete remission (CR), while the non-responder cohort consisted of 3 AML patients. Within the PB samples, the responder cohort consisted of 5 patients (3 MDS and 2 AML) at CR, 3 patients (1 MDS and 2 AML) at partial remission (PR), while the non-responder cohort had 4 patients (2 MDS and 2 AML). We also analyzed for any potential differences between MDS and AML patients as well as between patients at PR and CR, and found no significant differences in the proportion of TNFR2+ Tregs (data not shown). Patient characterization into clinical responders and non-responders were performed at EOC1 due to the higher patient numbers compared to EOC3.
Azacitidine and panobinostat treatment increases the low level of Th1 cytokines produced by CD4 effector T cells isolated from the BM.
We determined if azacitidine and panobinostat had an effect on CD4 effector T cell function within patients. CD4 effector T cells capable of IFNγ and IL-2 production were found to be predominantly FOXP3-T cells. Figure 5A shows the gating strategy to identify intracellular IFNγ and IL-2 production by CD4 effector T cells. Generally, CD4 T cells from the BM of patients produced relatively low levels of both IFNγ and IL-2 (Fig. 5A) . We also determined the effect of treatment on intracellular cytokine production on CD4 T cells from the PB and BM. There was no change in cytokine production by T cells isolated from the PB, but both IFNγ (p=0.05) and IL-2 (p=0.07) production by T cells from the BM of all patients was enhanced at the EOC1 when compared to screening samples (data not shown). Upon further delineation of patients into responders and nonresponders to treatment, there were no significant differences in cytokine production between responders and non-responders in PB. However, responders to treatment showed significant increases in IFNγ (6-fold higher; p=0.04) and an increase for IL-2 (12-fold higher) production by CD4 T cells from the BM at EOC1 when compared to non-responders (who had 1.1-fold higher for IFNγ and 1.4-fold higher for IL-2 production) (Fig. 5B) . As some effector T cells also express TNFR2 expression, we determined if TNFR2+ effector T cells were reduced on treatment within patients. Firstly, we observed that majority of effector T cells were TNFR2-, and these cells were significantly lower within the PB of patients compared to healthy donors, while there was no significant change observed in the percentages of TNFR2+ effector T cells (Fig. 5S) . On treatment, TNFR2-effector T cell levels were significantly enhanced while TNFR2+ effector T cells were significantly reduced within one month of treatment (Fig. 5S) . Additionally, upon analyzing cytokine production, we observed no differences in IFNγ or IL-2 production by TNFR2-as well as TNFR2+ effector T cells within the PB samples between responders and non-responders, while within the BM, it was the TNFR2-effector T cells and not the TNFR2+ subset within the responder patients that produced significantly higher levels of IFNγ compared to the non-responder patients (data not shown).
Panobinostat but not azacitidine lowers the frequency of TNFR2+ Tregs in vitro.
Our data, thus far, demonstrates Tregs in the PB of AML patients are decreased upon treatment with azacitidine and panobinostat and this decrease is driven by a reduction in the TNFR2+ Treg subset.
Moreover, a proportion of patients had this decrease within their BM. To determine if the decrease in TNFR2+ Treg percentages is due to changes in TNF levels, we assessed TNF levels within the serum of the PB and BM of patients. TNF levels were below detectable level for most patients at Scr as well as EOC1, and hence could not be further assessed (<6 pg/ml). To determine if an altered migration into the BM from the PB could account for the decrease in TNFR2+ Tregs within the BM of patients who responded to treatment, we firstly assessed any potential differences in CXCR4 expression levels on TNFR2+ Tregs. There was no significant difference observed within the CXCR4 levels on TNFR2+ Tregs at EOC1 when compared to Scr between the two patient cohorts (Fig. 6A) . Additionally, we assessed CXCL12 levels in the PB serum and BM fluid. CXCL12 levels at EOC1, when compared to screening were significantly higher in responder patients when compared to the non-responder patients (Fig. 6B) . This increase was seen within the PB serum as well as the BM fluid of these patients. However, as the level of CXCL12 was similar in the PB serum and the BM fluid within the responder patients, this suggests that the decrease in TNFR2+
Tregs may not be due to selective migration of these cells from the BM to the PB. To further elucidate other potential mechanisms that can result in the reduction of TNFR2+ Tregs, we assessed whether the treatment drugs, azacitidine and panobinostat can interfere with the induction of these cells in vitro. However, it has previously been demonstrated that an increase in Treg frequency was observed in vitro and also in vivo in high-risk MDS patients when treated with azacitidine (32) . To test whether azacitidine or panobinostat, or the combination was responsible for the Treg reductions, we performed in vitro functional assays. Azacitidine has been shown to be bioactive at 1 μM in vitro (32) and a range of doses were tested for panobinostat (alone or with azacitidine), since there are currently no studies that have tested the effect of panobinostat on T cells in vitro. We observed a dose-dependent decrease in the MFI levels of CD25 expression on CD4 T cells with increasing doses of panobinostat, both with and without azacitidine (Fig. 6C ). This effect was also reflected in FOXP3 and TNFR2 expression by CD4 T cells. Hence, the induction of CD25 hi FOXP3+TNFR2+ cells was decreased dose-dependently with increasing doses of panobinostat (Fig. 6D) . However, consistent with a previous study (32) , we also observed a significant increase in FOXP3 MFI within CD4 T cells upon azacitidine treatment alone when compared to no treatment ( 
Discussion
The interplay between Tregs and AML blasts has been well documented. To enhance anti-tumor immunity, it is crucial to identify and target the most active Treg population within AML patients. Tregs. Our data along with these studies suggest that a complex network involving TNF/TNFR2 and CXCL12/CXCR4 interactions exists, enabling both AML cells as well as TNFR2+ Tregs to flourish by creating an immunosuppressive niche within AML patients. This is intriguing, as CXCR4 expression has previously been associated with disease progression in AML patients (47) .
Our results demonstrate that although there was a decrease in TNFR2+ Treg percentages within the PB of both the responder and non-responder patients on treatment, a reduction of TNFR2+ 
Tregs was observed only in the BM of the responder patients. This suggests that for patients to clinically respond, it may be essential to reduce Treg proportions within the BM as well as PB.
Consequently, we observed increases in both IFNγ and IL-2 production by CD4 effector T cells isolated from the BM within one month of treatment of responders. We believe this increase in Th1 cytokines from patients who responded to treatment was a corollary effect of TNFR2+ Treg reduction within the BM and not a direct effect of the treatment, as both azacitidine and panobinostat failed to significantly enhance cytokine production in vitro (Fig. 6S) . Although the precise mechanisms that result in a reduction of TNFR2+ Tregs within the BM of responder patients and the PB of all patients is currently unclear, we believe this may be due to several factors. Firstly, we observed that the responder patients had significantly higher levels of CXCL12 levels in both the BM fluid and PB serum at EOC1, compared to non-responder patients. Although, as previously in the BM, whether increasing the concentration of the drugs given to these patients may alter their outcome remains to be determined. Moreover, whether the addition of other chemotherapeutic drugs like lenalidomide, which has been previously demonstrated to increase IFNγ and IL-2 production by T cells, may be beneficial to the non-responders still needs to be evaluated (49) . However, due to the adverse side effects of a higher drug dosage or an additional drug to a combinatorial therapy, alternative options will need to be considered with caution. 
